Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease
Oveis Jamialahmadi(University of Gothenburg), Stefano Romeo(Sahlgrenska University Hospital), Frits R. Rosendaal(Leiden University Medical Center), Julia Kozlitina(Southwestern Medical Center), Luca Valenti(University of Milan), Päivi Pajukanta(University of California, Los Angeles), Marcus Alvarez(University of California, Los Angeles), Ruifang Li‐Gao(Leiden University Medical Center), Samantha Maurotti(Magna Graecia University), Antonio De Vincentis(Università Campus Bio-Medico), Francesco Malvestiti(University of Milan), Kyla Gelev(University of California, Los Angeles), Rosellina Margherita Mancina(Università Campus Bio-Medico), François Pattou(Inserm), Federica Tavaglione(Università Campus Bio-Medico), Umberto Vespasiani‐Gentilucci(Università Campus Bio-Medico)
Cited by 100
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
|Journal of Hepatology|2024|1.6k
Incidence and mortality of venous thrombosis: a population‐based study
|Journal of Thrombosis and Haemostasis|2007|1.4k